Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

Jacobs enters the final quarter of FY2026 with record backlog, a 1.4x trailing-twelve-month book-to-bill ratio, broad Infrastructure & Advanced Facilities growth and guidance raised for a third consecutive quarter. These indicators support continued growth and margin expansion, while the FY2029 framework offers additional upside through 6%-8% organic adjusted-net-revenue growth and a 16%+ adjusted EBITDA margin. At the issuer-reported market price of $151.98, however, a meaningful portion of this execution appears reflected in the shares. PA Consulting integration, elevated acquisition-related adjustments, project-award timing and exposure to client capital-spending or government-funding changes warrant a Hold rather than a more aggressive rating.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026
Low · most bearish analyst$144.00
Mean target$162.53
High · most bullish analyst$181.00
Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$144.0018%

Book-to-bill falls below 1.0x, project awards or client capital programs are delayed, adjusted EBITDA margin drops below FY2026 guidance and PA Consulting synergies lag. Under that combination, the FY2029 framework loses credibility and the shares de-rate from the issuer-displayed current price.

Base CaseCentral scenario
$162.5358%
Matches the consensus mean

Jacobs delivers near the raised FY2026 guidance ranges and makes steady progress toward its FY2029 framework, but normalization from exceptionally strong bookings and integration demands limit multiple expansion.

Bull CaseUpside scenario
$181.0024%

Sustained data-center, semiconductor, energy, transportation and water demand keeps book-to-bill materially above 1.0x; Jacobs meets or exceeds its FY2029 growth and margin targets, realizes at least $20 million of annual PA Consulting cost synergies and converts its record backlog without material execution losses.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • Record $28.9 billion backlog and a 1.4x trailing-twelve-month book-to-bill ratio provide unusually strong forward workload visibility.
  • Q3 FY2026 adjusted net revenue increased 8.3%, adjusted EBITDA increased 16.7% and adjusted EBITDA margin reached 15.2%, indicating operating leverage.
  • Management raised FY2026 guidance for a third consecutive quarter and continues to target 6%-8% organic adjusted-net-revenue CAGR, 16%+ adjusted EBITDA margin and 10%+ free-cash-flow margin by FY2029.
Sign in / Sign up to read more
Key Investment Risks
  • The PA Consulting acquisition creates integration, retention and synergy-execution risk; Jacobs also reported substantial acquisition-related compensation, transaction and restructuring adjustments during FY2026.
  • Project awards and funding can be delayed or reduced by client financial conditions, government-budget changes, tariffs, interest rates or weaker capital spending.
  • Backlog is not guaranteed revenue, and a fall in book-to-bill below 1.0x or weaker project execution would undermine the growth and margin-expansion thesis.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.